{ "A Study of Precemtabart Tocentecan for Metastatic Colorectal Cancer", "This study is for people with metastatic colorectal cancer (cancer that has spread) who have already received certain standard treatments. It aims to see if a new treatment, Precemtabart tocentecan (Precem-TcT), either alone or with Bevacizumab, can help people live longer compared to a standard treatment called Trifluridine/Tipiracil plus Bevacizumab. You could be eligible if you are 18 or older, have metastatic colorectal cancer, and your cancer has not responded to or has progressed after up to two previous systemic treatments. The study is looking to enroll 1020 participants, but its current status is unclear.", "design": "This is an interventional study planning to enroll 1020 participants. It compares different treatment approaches for metastatic colorectal cancer.", "commitments": "Precemtabart tocentecan and Bevacizumab are given intravenously (into a vein) every 2 or 3 weeks. Trifluridine/Tipiracil is taken orally (by mouth) twice daily for specific days each month.", "compensation": "Not stated in the trial record.", "follow_up": "Overall survival will be measured, with assessments continuing for approximately 19 months after randomization.", }

Study design

Not specified.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.